Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Multani

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Journal of Hematology|January 7, 2003
Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphomaP Multani
Cancer Research|October 10, 1998
Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lectureB A Chabner, A L Boral, P Multani
Current Pharmaceutical Biotechnology|January 5, 2002
Non-Hodgkin's lymphoma: review of conventional treatmentsP Multani, C A White, A Grillo-López
Epilepsia|July 1, 1994
Neocortical dendritic pathology in human partial epilepsy: a quantitative Golgi studyP Multani, R H Myers, H W Blume, et al.
Leukemia & Lymphoma|January 24, 2003
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan, L A Peterson, S A Kent, et al.
Bone Marrow Transplantation|February 2, 2000
High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II studyH C Toh, S L McAfee, R Sackstein, et al.
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
AntimetabolitesJ L Grem, C H Takimoto, P Multani, et al.
Current Pharmaceutical Biotechnology|January 5, 2002
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphomaA J Grillo-López, B K Dallaire, A McClure, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 25, 2000
Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignanciesT R Spitzer, S McAfee, R Sackstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Hematology|January 7, 2003
Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphomaP Multani
Cancer Research|October 10, 1998
Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lectureB A Chabner, A L Boral, P Multani
Current Pharmaceutical Biotechnology|January 5, 2002
Non-Hodgkin's lymphoma: review of conventional treatmentsP Multani, C A White, A Grillo-López
Epilepsia|July 1, 1994
Neocortical dendritic pathology in human partial epilepsy: a quantitative Golgi studyP Multani, R H Myers, H W Blume, et al.
Leukemia & Lymphoma|January 24, 2003
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan, L A Peterson, S A Kent, et al.
Bone Marrow Transplantation|February 2, 2000
High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II studyH C Toh, S L McAfee, R Sackstein, et al.
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
AntimetabolitesJ L Grem, C H Takimoto, P Multani, et al.
Current Pharmaceutical Biotechnology|January 5, 2002
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphomaA J Grillo-López, B K Dallaire, A McClure, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 25, 2000
Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignanciesT R Spitzer, S McAfee, R Sackstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
Pageof 1